Financial Performance - Enovis reported fourth-quarter 2025 net sales of $576 million, a 3% increase on a reported basis and 2% on an organic basis compared to Q4 2024[3]. - For the full year 2025, Enovis achieved net sales of $2.2 billion, reflecting a 7% growth on a reported basis and 6% on an organic basis[6]. - The company reported a net loss of $1,183.6 million for the year ended December 31, 2025, compared to a net loss of $824.8 million for the year ended December 31, 2024[25]. - Enovis Corporation reported a net loss of $520.5 million for the three months ended December 31, 2025, compared to a net loss of $703.2 million for the same period in 2024, reflecting an improvement in net loss margin from (125.4)% to (90.4)%[25]. - The full year 2025 net loss from continuing operations was $1,182 million, including a non-cash goodwill impairment charge of $1,050 million[7]. - The company reported a net loss of $1,183.6 million for the year ended December 31, 2025, compared to a net loss of $824.8 million in 2024[35]. Sales Growth - Reconstructive sales for the full year 2025 grew 10% year-over-year on a reported basis and 8% on an organic basis[8]. - Prevention & Recovery sales for the full year 2025 increased by 4% year-over-year on both a reported and organic basis[8]. - Net sales for Q4 2025 reached $575.8 million, a 2.6% increase from $561.0 million in Q4 2024[37]. - For the year ended December 31, 2024, total net sales were $2,107.6 million, with an increase of 6.7% year-over-year[39]. - For the year ended December 31, 2025, total net sales are projected to be $2,248.0 million, indicating continued growth[39]. Future Projections - Enovis expects 2026 revenue to be in the range of $2.31-2.37 billion, representing 4-6% organic revenue growth[10]. - Adjusted EBITDA for 2026 is projected to be between $425-435 million[10]. - Full-year adjusted earnings per share for 2026 is anticipated to be in the range of $3.52 to $3.73[10]. Adjusted Financial Metrics - Adjusted net income from continuing operations (non-GAAP) for the three months ended December 31, 2025, was $54.8 million, with an adjusted net income margin of 9.5%, slightly down from $55.0 million and 9.8% in the same period of 2024[25]. - Adjusted EBITDA (non-GAAP) for the year ended December 31, 2025, was $403.0 million, with an adjusted EBITDA margin of 17.9%, consistent with the previous year[28]. - Adjusted gross profit for Q4 2025 was $353.6 million, with an adjusted gross profit margin of 61.4%, compared to 60.1% in Q4 2024[31]. Impairment and Charges - The company experienced a net loss from continuing operations of $519 million in Q4 2025, which included a non-cash goodwill impairment charge of $501 million[4]. - The company incurred a goodwill impairment charge of $501.3 million for the three months ended December 31, 2025, compared to $645.0 million for the same period in 2024[28]. - Strategic transaction costs related to the Lima Acquisition amounted to $19.2 million for the three months ended December 31, 2025, compared to $13.3 million in the same period of 2024[28]. - The company recognized a charge of $45.8 million for the net present value of royalty interest purchases, which will be paid over nine years[30]. Asset and Liability Changes - Total current assets increased to $1,207.1 million in 2025 from $1,146.4 million in 2024[33]. - Total liabilities rose to $2,342.8 million in 2025, up from $2,154.4 million in 2024[33]. - Cash and cash equivalents decreased to $36.4 million at the end of 2025 from $48.2 million at the end of 2024[35]. Market Dynamics - The company experienced a 10.6% decline in U.S. Other Prevention & Recovery sales, dropping from $70.2 million in Q4 2024 to $62.8 million in Q4 2025[37]. - International Reconstructive sales grew by 12.4% in Q4 2025, reaching $151.8 million compared to $135.0 million in Q4 2024[37]. - Existing businesses contributed $10.3 million to total sales, reflecting a growth of 1.8%[39]. - The contribution from existing businesses for the year was $123.5 million, representing a growth of 5.9%[39]. - Foreign currency translation positively impacted sales by $30.0 million for the year ended December 31, 2024, accounting for a 1.4% increase[39]. - The impact of acquisitions for the year ended December 31, 2024, was $4.2 million, contributing 0.2% to total sales[39]. - Divestitures resulted in a decrease of $17.3 million in sales for the year ended December 31, 2024, which is a decline of 0.8%[39]. - Foreign currency translation effects for the three months ended December 31, 2024, added $16.0 million to total sales, a 2.9% increase[39]. - The company experienced a decline of $13.0 million from divestitures in the three months ended December 31, 2024, which is a 2.3% decrease[39].

Core Viewpoint Enovis Corporation reported its financial results for the fourth quarter and full year of 2025, highlighting a mixed performance with a notable net loss primarily due to a significant goodwill impairment charge, while also indicating growth in net sales and expectations for 2026. Financial Results Summary Fourth Quarter 2025 - Enovis' net sales reached $576 million, reflecting a 3% increase on a reported basis and 2% on an organic basis compared to Q4 2024 [2] - The Global Reconstructive segment saw a 7% increase in net sales on a reported basis, with 3% organic growth, while the Prevention & Recovery segment experienced a 1% decline on a reported basis and remained flat organically [2] - The company reported a net loss from continuing operations of $519 million, which included a non-cash goodwill impairment charge of $501 million [3][4] - Adjusted EBITDA for the quarter was $112 million [3] Full Year 2025 - Total net sales for 2025 were $2.2 billion, representing a 7% increase on a reported basis and 6% on an organic basis [5] - The Reconstructive segment grew by 10% on a reported basis and 8% organically, while the Prevention & Recovery segment grew by 4% on both bases [5] - The full year net loss from continuing operations was $1,182 million, including a non-cash goodwill impairment charge of $1,050 million [6] - Adjusted EBITDA for the year was $403 million, with adjusted earnings per diluted share of $3.30 [6] Management Commentary - The CEO of Enovis stated that the performance in 2025 reflects meaningful operational progress, effective operations in a dynamic environment, and above-market organic growth [7] - The company aims to maintain a disciplined focus on commercial execution, innovation, operational efficiency, and financial discipline as it prepares for sustainable growth in 2026 [8] 2026 Financial Outlook - Enovis expects revenue for 2026 to be in the range of $2.31 to $2.37 billion, indicating 4-6% organic revenue growth [8] - Adjusted EBITDA is projected to be between $425 million and $435 million, with adjusted earnings per share expected to range from $3.52 to $3.73 [8]

Core Insights - Smaller med-tech companies may present a value trap unless they demonstrate significant growth, as many institutions are reluctant to consider them without growth metrics [1] Industry Analysis - The med-tech sector is characterized by a focus on growth, with smaller companies needing to distinguish themselves to attract institutional investment [1]

Enovis Corporation (NYSE:ENOV) is included in our list of the 14 oversold value stocks to invest in right now. Evercore ISI Bullish on Enovis (ENOV) Despite Weak Share Price Momentum Pixabay/Public domain Enovis Corporation (NYSE:ENOV) underwent a challenging period in 2025 amid macro headwinds. With the stock down 50% over the past year, the shares ended-up hitting their 52-week low on January 29, 2026, closing at $21.00. Amid weak investor momentum, Enovis Corporation (NYSE:ENOV) drew attention from ...

Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, UT. About Enovis Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes an ...

Core Viewpoint - Enovis Corporation will host an investor conference call and live webcast to discuss its fourth quarter and full year 2025 financial results on February 26, 2026, at 8:30 a.m. Eastern Time [1] Group 1: Conference Call/Webcast Information - Investors can access the live webcast via a link on the Enovis website, and participants can join the call by dialing (833) 685-0901 for U.S. callers and (412) 317-5715 for international callers [2] - A replay of the call will be available on the Enovis website later that day [2] Group 2: About Enovis - Enovis Corporation is an innovation-driven medical technology growth company focused on developing clinically differentiated solutions that improve patient outcomes and transform workflows [3] - The company offers a wide range of products, services, and integrated technologies aimed at supporting active lifestyles in orthopedics and beyond [3] - Enovis shares are listed on the New York Stock Exchange under the symbol ENOV [3] Group 3: Availability of Information - Enovis routinely announces material information to investors through SEC filings, press releases, public conference calls, webcasts, and its Investor Relations website [4] - The company encourages investors and the media to review the information shared on its Investor Relations website [4]

Group 1 - Enovis Corporation (NYSE:ENOV) is recognized as a promising investment opportunity with a Buy rating and a price target of $41 initiated by BTIG, reflecting confidence in the company's long-term prospects in orthopedic care [1][2] - The company has achieved consistent organic revenue growth in the mid-single-digit to high-single-digit range across its Reconstruction and Prevention & Recovery segments, with expectations for accelerated growth in 2026 due to new product launches [2][3] - UBS has adjusted its price target for Enovis to $50 from $57 while maintaining a Buy rating, forecasting sales of $2.26 billion in 2025, $2.37 billion in 2026, and $2.52 billion in 2027, driven by new product launches [3] Group 2 - Enovis Corporation is a global medical technology company focused on musculoskeletal health, offering solutions that improve patient outcomes in reconstruction, rehabilitation, and pain management through orthopedic devices and surgical implants [4]

Core Insights - The health care sector has several oversold stocks that present buying opportunities for undervalued companies [1] Group 1: Oversold Stocks - Travere Therapeutics Inc (NASDAQ:TVTX) has an RSI of 29.7, with a stock price decline of approximately 23% over the past month and a 52-week low of $12.91 [6] - Hims & Hers Health Inc (NYSE:HIMS) has an RSI of 29.7, with a stock price decline of around 13% over the past month and a 52-week low of $23.97 [6] - Enovis Corp (NYSE:ENOV) has an RSI of 29.6, with a stock price decline of about 14% over the past five days and a 52-week low of $22.98 [6] Group 2: Analyst Ratings and Price Targets - Evercore ISI Group initiated coverage on Hims & Hers Health with an In-Line rating and a price target of $33 [6] - BTIG analyst initiated coverage on Enovis with a Buy rating and a price target of $41 [6] - Travere Therapeutics' new PDUFA target action date for Filspari is set for April 13 [6]

Core Insights - The health care sector shows potential investment opportunities as several stocks are identified as oversold, with Relative Strength Index (RSI) values near or below 30, indicating they may be undervalued [1][2] Company Summaries - **Travere Therapeutics Inc (NASDAQ:TVTX)**: The company’s stock has fallen approximately 23% over the past month, reaching a 52-week low of $12.91. The RSI value is 29.7, and the stock closed at $27.94, with a momentum score of 91.85 [3][6] - **Hims & Hers Health Inc (NYSE:HIMS)**: The stock has decreased around 13% in the last month, with a 52-week low of $23.97. The RSI value is 29.7, and shares closed at $30.47 after a 2.9% drop [4][6] - **Enovis Corp (NYSE:ENOV)**: The stock has seen a decline of about 14% over the past five days, with a 52-week low of $22.98. The RSI value is 29.6, and shares closed at $23.09, down 3.7% [5][6]

Core Thesis - Enovis Corporation is viewed positively due to its dual-engine economic model that combines a high-margin implant franchise with a lower-margin prevention and recovery business, which is expected to drive growth and stability in revenue streams [1][2]. Business Model - Enovis operates in the musculoskeletal healthcare sector, focusing on proprietary orthopedic implants for surgeries, which generate durable revenue due to high switching costs and surgeon loyalty [2][3]. - The prevention and recovery segment includes braces and therapy devices, increasingly bundled with the MotionMD software platform to create a more stable revenue stream through workflow integration [3]. Competitive Position - Enovis competes against larger companies like Stryker and Zimmer Biomet but leverages specialization and agility to fill market gaps through targeted acquisitions, such as LimaCorporate [4]. - The company is in an aggressive scaling phase, supported by significant investments in R&D and inventory, although this is accompanied by elevated leverage that may limit financial flexibility [4]. Management Strategy - Management focuses on organic growth, margin expansion, and successful integration of acquisitions, prioritizing these over short-term GAAP earnings, with a view towards deleveraging as a critical future milestone [5]. - The investment case relies on effective integration, sustained surgeon adoption, and disciplined capital allocation, indicating strong underlying economics but necessitating careful monitoring of execution and balance-sheet risks [5].